Literature DB >> 3128351

Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.

C T Smit Sibinga1, P J Schulting, J Notebomer, P C Das, J Marrink, J vd Meer.   

Abstract

In an attempt to implement the small pool concept in Factor VIII purification, cryoprecipitate derived from heparinised plasma was reprecipitated in the cold providing a factor VIII concentrate for freeze drying and heat treatment. There was considerable purification; only 1% of the original plasma proteins was left in the final product. Factor VIII:C concentration was about 19 IU/ml. Factor VIII related antigen (RAg) appeared heterogeneous, with a broad base and asymmetry on crossed immunoelectrophoresis. Fibrinogen content was 15 g/l. In contrast to high-purity commercial concentrates, fibronectin was considerably concentrated. Immunoglobulin contents were similar to a high-purity commercial product. The amount of other plasma proteins was very small, varying from less than 0.2% for C3 complement to 2.3% ceruloplasmin. In some respects the preparation may be considered as an intermediate-purity Factor VIII concentrate. Following addition of 2% sucrose before freeze drying, Factor VIII, total protein and fibrinogen remain virtually stable (less than 15% loss) during heating of the material to 60, 64 or 68 degrees C for 24 to 72 h without changes of protein spectrum following heating. The heated product when stored at 4 degrees C remains stable for at least 3 months. In two severe haemophiliacs receiving this heat treated product, in vivo Factor VIII recovery was 100% with a mean half life of 10.2 h.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128351     DOI: 10.1007/bf00320015

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  22 in total

1.  Characteristics of various factor VIII concentrates used in treatment of haemophilia A.

Authors:  I M Nilsson; U Hedner
Journal:  Br J Haematol       Date:  1977-12       Impact factor: 6.998

2.  Case for concluding that heat-treated, licensed anti-haemophilic factor is free from HTLV-III.

Authors:  J C Petricciani; J S McDougal; B L Evatt
Journal:  Lancet       Date:  1985-10-19       Impact factor: 79.321

3.  Wet heating for safer factor VIII concentrate?

Authors:  P B Kernoff; E J Miller; G F Savidge; S J Machin; M S Dewar; F E Preston
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

4.  In vitro and in vivo characterization of factor VIII preparations.

Authors:  J P Allain; F Verroust; J P Soulier
Journal:  Vox Sang       Date:  1980-02       Impact factor: 2.144

5.  Fibronectin-complex (FN-C) present in normal plasma.

Authors:  J Marrink; S vd Geest; R Sinnema; E Vellenga; E G de Vries
Journal:  Thromb Res       Date:  1985-03-15       Impact factor: 3.944

6.  In vivo effectiveness of a high-yield factor VIII concentrate prepared in a blood bank.

Authors:  G Rock; R K Smiley; P Tittley; D S Palmer
Journal:  N Engl J Med       Date:  1984-08-02       Impact factor: 91.245

Review 7.  Biometric principles in clotting and clot lysis assays.

Authors:  T B Kirkwood; T J Snape
Journal:  Clin Lab Haematol       Date:  1980

8.  Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.

Authors:  C T Smit Sibinga; S M Daenen; G W van Imhoff; A Maas; P C Das
Journal:  Thromb Haemost       Date:  1984-02-28       Impact factor: 5.249

9.  Fibronectin in blood products--an in vitro and in vivo study.

Authors:  J T Reilly; B A McVerry; M J Mackie
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

10.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.